Our Process Development teams design phase-appropriate manufacturing processes built for scalable transfer into cGMP execution.
By integrating upstream and downstream development, analytical strategy, and manufacturing alignment early, Artis helps reduce transfer risk and accelerate timelines into clinical production.
Artis-manufactured synthetic DNA can be incorporated as the starting material to support tighter process control and streamlined supply chain management.
Scalable process development across a broad range of cell therapy applications, including oncology, regenerative medicine, autoimmune, and rare disease programs, with experience in:
Programs using Artis-manufactured synthetic DNA benefit from integrated supply chain control and reduced lead times.
Manufacturing-focused process development for:
Flexible, innovation-driven process development support for scalable non-viral delivery systems, including:
Manufacturing-focused process development for synthetic DNA applications, with integrated downstream GMP capabilities:
Structured documentation systems support traceability, reproducibility, and efficient technology transfer into GMP manufacturing and Quality Control.
Stem Cells 
AAV Delivery 
LVV Delivery 
Extracellular Vesicles 
Nanoparticles